Translational Lung Cancer Research《肺癌转化研究》(可官网投稿)

Translational Lung Cancer Research《肺癌转化研究》(月刊). Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.

杂志简称:transl lung cancer r
中文译名:《肺癌转化研究》
收录属性:scie(2024版), 目次收录(维普), 目次收录(知网),英文期刊,
投稿方向:医学、respiratory system呼吸系统、oncology肿瘤学

Translational Lung Cancer Research《肺癌转化研究》

SCI/E期刊基本信息

出版周期:月刊 地区:中国香港
中科院分区:3区
是否TOP:非TOP期刊
是否综述:非综述期刊
是否OA:OA期刊
国际标准刊号:ISSN 2218-6751;EISSN 2226-4477
杂志语言:英语
出版国家:中国香港

杂志官网 联系方式

出版地址:AME PUBLISHING COMPANY ,FLAT-RM C 16F,KINGS WING PLAZA 1,NO 3 KWAN ST,SHATIN,PEOPLES R CHINA,HONG KONG,00000
杂志邮箱:
投稿网址:https://tlcr.amegroups.com/author/submit
杂志官方网址:https://tlcr.amegroups.com/
出版商网址:http://www.amepc.org

杂志投稿要求

刊知网提示:

1、投稿方式:进入官网系统在线投稿。

2、期刊网址:https://tlcr.amegroups.com/

3、投稿网址:https://tlcr.amegroups.com/author/submit

4、官网邮箱:editor@tlcr.org

5、出版周期:月刊,一年出版12期。

刊知网 精心整理,转载请注明出处:https://www.kanzhiwang.com/archives/44651

我要点评 请您把投稿经验分享出来 让大家少走弯路少踩坑,我为人人、人人为我。

内容纠错 您如果发现杂志信息有错漏 可以在下方留言。

上一篇 2024年11月9日 下午12:08
下一篇 2024年11月9日 下午12:08

相关推荐

发表回复

登录后才能评论

评论列表(1条)

  • 李达龙的头像
    李达龙 2023年6月6日 下午6:13

    审稿时间:15天
    文章字数:6500字
    我的学历:硕士
    录用情况:直接录用
    是否回复:有自动回复
    见刊周期:1个月
    投稿主题:L临床研究
    期刊点评:速度快,很快初审就给拒绝了。 感觉有点难审稿。以下是邮件回复Manuscript ID: TLCR-23-36–Title: (题目–)Dear Dr. –,Your manuscript, noted above, has been reviewed in-house by the Editors of Translational Lung Cancer Research and I regret to report that it has not been accepted for publication.In order to expedite the review process, the Editorial Office currently uses a two-step procedure: The first involves a screening review by the Editors to determine whether or not the manuscript qualifies for the second step, a peer review. Unfortunately, the initial review of your manuscript indicates that it does not have sufficient priority for acceptance. Thank you for submitting your manuscript to Translational Lung Cancer Research.We are letting you know about this decision now so that you can promptly submit to another journal.The significant increase in submissions of manuscripts to the Journal has resulted in intense competition for available space. The Editors have therefore had to raise the bar in defining the criteria for acceptability for publication. As a result, many well conducted studies and interesting reports previously acceptable to the Translational Lung Cancer Research must now, unfortunately, be declined.We hope our decision to decline your manuscript at this time does not deter you from submitting a paper to us in the future. Thank you for allowing us to consider your manuscript for our journal.Yours sincerely,Editorial Office______________________________Translational Lung Cancer ResearchEmail: editor@tlcr.orgURL: https://tlcr.amegroups.com

联系我们

191 1833 1195

在线咨询: QQ交谈

邮件:321628655@qq.com

工作时间:周一至周五,9:30-18:30,节假日休息